Market research
56S1.F Sartorius Stedim Biotech S.A
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 19B
- P/E ratio
- 64.09
- Analyst target
- Not available
- Dividend yield
- 0.4%
- Beta
- 1.14
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- FR0013154002
- Market cap
- 19B
- P/E ratio
- 64.09
- Analyst target
- Not available
- Dividend yield
- 0.4%
- Beta
- 1.14
About
About Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 56S1.F discussion.
5 years, 5 months ago
Sartorius Stedim Biotech S.A is currently in a long term uptrend where the price is trading 27.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.9.
Sartorius Stedim Biotech S.A's total revenue rose by 45.8% to $531M since the same quarter in the previous year.
Its net income has increased by 107.4% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 84.4% to $8M since the same quarter in the previous year.
Based on the above factors, Sartorius Stedim Biotech S.A gets an overall score of 4/5.